S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
LON:VRCI

Verici Dx (VRCI) Share Forecast, Price & News

GBX 8
-1.00 (-11.11%)
(As of 04:40 PM ET)
Compare
Today's Range
8
▼
8.15
50-Day Range
8.51
▼
11.98
52-Week Range
4.53
▼
19
Volume
1.22 million shs
Average Volume
255,581 shs
Market Capitalization
£13.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlines

VRCI stock logo

About Verici Dx (LON:VRCI) Stock

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company also develops Protega, a peripheral blood-based test that aims to predict the risk of fibrosis and long-term graft failure. Verici Dx plc was incorporated in 2020 and is based in Penarth, the United Kingdom.

VRCI Price History

VRCI Stock News Headlines

September 23, 2023 | americanbankingnews.com
Verici Dx (LON:VRCI) Trading Up 6.8%
July 25, 2023 | finance.yahoo.com
Companies Like Verici Dx (LON:VRCI) Could Be Quite Risky
September 29, 2023 | PressReach (Ad)
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
May 25, 2023 | finance.yahoo.com
DX - Dynex Capital, Inc.
February 16, 2023 | finance.yahoo.com
Cloud DX Announces Private Placements of up to an Aggregate of $5.5 Million with Lead Orders of $1.5 Million
February 15, 2023 | finance.yahoo.com
We're Keeping An Eye On Verici Dx's (LON:VRCI) Cash Burn Rate
January 18, 2023 | benzinga.com
Dynex Cap Stock (NYSE:DX), Quotes and News Summary
September 8, 2022 | finance.yahoo.com
We Think Verici Dx (LON:VRCI) Needs To Drive Business Growth Carefully
September 29, 2023 | PressReach (Ad)
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
September 3, 2022 | uk.finance.yahoo.com
Verici Dx plc (VRCI.L)
June 14, 2022 | marketwatch.com
Verici Releases Data on Tuteva Blood Test; Shares Dive
May 5, 2022 | finance.yahoo.com
American Shared Hospital Services Announces First Quarter 2022 Earnings Conference Call
April 9, 2022 | lse.co.uk
Verici Dx Share Chat
March 26, 2022 | investing.com
Verici Dx Plc (VRCI)
See More Headlines
Receive VRCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verici Dx and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:VRCI
CUSIP
N/A
CIK
N/A
Web
www.vericidx.com
Phone
44 207 9338780
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-11,410,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-97.11%
Return on Assets
-49.55%

Debt

Debt-to-Equity Ratio
6.08
Current Ratio
4.59
Quick Ratio
8.49

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
GBX 6.09 per share
Price / Cash Flow
1.31
Book Value
GBX 7 per share
Price / Book
1.14

Miscellaneous

Outstanding Shares
170,320,000
Free Float
N/A
Market Cap
£13.63 million
Optionable
Not Optionable
Beta
1.19
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Sara Barrington A.C.A. (Age 55)
    A.C.I.M., CEO & Exec. Director
    Comp: $355.81k
  • Mr. David M. Anderson (Age 60)
    Chief Financial Officer
  • Mr. Salim Gulamabbas Hamir F.C.A.
    Company Sec.

Key Competitors

View All Competitors













VRCI Stock - Frequently Asked Questions

How have VRCI shares performed in 2023?

Verici Dx's stock was trading at GBX 12.50 on January 1st, 2023. Since then, VRCI shares have decreased by 36.0% and is now trading at GBX 8.
View the best growth stocks for 2023 here.

What is Verici Dx's stock symbol?

Verici Dx trades on the London Stock Exchange (LON) under the ticker symbol "VRCI."

How do I buy shares of Verici Dx?

Shares of VRCI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Verici Dx's stock price today?

One share of VRCI stock can currently be purchased for approximately GBX 8.

How much money does Verici Dx make?

Verici Dx (LON:VRCI) has a market capitalization of £13.63 million. The company earns £-11,410,000.00 in net income (profit) each year or GBX (0.06) on an earnings per share basis.

How can I contact Verici Dx?

Verici Dx's mailing address is Avon House, 19 Stanwell Road, Penarth CF64 2EZ, United Kingdom, . The official website for the company is www.vericidx.com. The company can be reached via phone at 44 207 9338780.

This page (LON:VRCI) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -